What are the treatment options for pancreatic cancer?

Pancreatic Cancer Treatment

Treatment Strategy Based on Disease Stage and Performance Status

For resectable pancreatic cancer (Stage I-II), proceed directly to surgical resection followed by 6 months of adjuvant chemotherapy with either gemcitabine or 5-fluorouracil. 1, 2

---

Resectable Disease (Stage I and Select Stage II)

Surgical Approach

• Perform pylorus-preserving pancreaticoduodenectomy for pancreatic head tumors and distal pancreatectomy with splenectomy for body/tail tumors 2
• Achieve R0 resection (negative margins on all seven margins) as this is the most critical prognostic factor 1, 2
• Remove ≥15 lymph nodes during standard lymphadenectomy to allow adequate pathologic staging 1
• Refer patients to high-volume specialized centers, as surgical team experience significantly impacts outcomes 2

Adjuvant Chemotherapy

• Administer 6 months of either gemcitabine (1000 mg/m² over 30 minutes weekly for 7 weeks, then 1 week rest, followed by 3 weeks on/1 week off) or 5-fluorouracil with folinic acid 1, 3
• Do NOT give adjuvant chemoradiation outside of clinical trials—this approach lacks survival benefit 1
• Adjuvant chemotherapy benefits even patients with R1 (positive margin) resections 1

---

Borderline Resectable Disease (Select Stage IIA)

Treat borderline resectable tumors with neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine plus nab-paclitaxel) followed by reassessment for surgical resection. 1, 2, 4

• Neoadjuvant therapy may increase R0 resection rates and identify patients unlikely to benefit from surgery 1, 2
• After 3-4 months of chemotherapy, consider adding chemoradiation (capecitabine with radiotherapy) before surgery 1
• Do not proceed to surgery if metastases develop or local progression occurs during neoadjuvant treatment 1

---

Locally Advanced Unresectable Disease (Stage IIB-III)

Initiate 6 months of gemcitabine monotherapy (1000 mg/m² over 30 minutes weekly) as the standard first-line treatment. 1, 5

Alternative First-Line Options Based on Patient Selection

• For patients ≤75 years with ECOG performance status 0-1 and bilirubin ≤1.5× ULN, use FOLFIRINOX (5-FU 400 mg/m² bolus then 2400 mg/m² over 46 hours, leucovorin 400 mg/m², irinotecan 180 mg/m², oxaliplatin 85 mg/m² every 2 weeks) 1, 5
• Consider chemoradiation (capecitabine with radiotherapy) only for patients with good performance status who remain stable after 3 months of gemcitabine without progression 1

Second-Line Treatment

• After gemcitabine failure, use the OFF regimen (5-FU 2000 mg/m² over 24 hours, leucovorin 200 mg/m², oxaliplatin 85 mg/m² every 2 weeks) 5

---

Metastatic Disease (Stage IV)

Treatment selection depends strictly on performance status and bilirubin level:

Excellent Performance Status (ECOG 0-1, Bilirubin ≤1.5× ULN)

• Use either FOLFIRINOX or gemcitabine (1250 mg/m²) plus nab-paclitaxel (125 mg/m²) on Days 1,8, and 15 of each 28-day cycle 1, 6
• FOLFIRINOX provides superior overall survival but with significantly higher toxicity—reserve for younger patients (≤75 years) 1, 6

Moderate Performance Status (ECOG 2 or Bilirubin 1.5-3× ULN)

• Use gemcitabine monotherapy (1000 mg/m² over 30 minutes weekly) 1, 6
• In highly selected ECOG 2 patients with heavy tumor burden, consider gemcitabine plus nab-paclitaxel for best response chance 1

Poor Performance Status (ECOG 3-4)

• Provide supportive care only—do not administer chemotherapy 1, 6

Second-Line Treatment After Progression

• After first-line gemcitabine: use OFF regimen or nanoliposomal irinotecan (70 mg/m²) with 5-FU/leucovorin 5, 6
• After first-line FOLFIRINOX: use gemcitabine monotherapy 1, 6

---

Palliative and Supportive Care Interventions

Biliary Obstruction

• Place metallic biliary stents endoscopically—this is safer than percutaneous insertion and as effective as surgical bypass 1, 6
• Use metal stents for patients with life expectancy >3 months; plastic stents require replacement every 6 months 1, 6

Duodenal Obstruction

• Place expandable metal stents endoscopically rather than performing surgical bypass 1, 6
• Use metoclopramide to improve gastric emptying 1

Pain Management

• Administer oral morphine as first-line analgesic 1, 5, 6
• Consider percutaneous or EUS-guided celiac plexus blockade for patients with poor opioid tolerance 1, 5, 6
• Use hypofractionated radiotherapy to improve pain control and reduce analgesic requirements 1, 5, 6

---

Critical Pitfalls to Avoid

• Never use adjuvant chemoradiation outside clinical trials—multiple studies show no survival benefit and potential harm 1
• Do not combine gemcitabine with other cytotoxics (5-FU, irinotecan, cisplatin, oxaliplatin) in first-line metastatic disease unless using the validated FOLFIRINOX or gemcitabine/nab-paclitaxel regimens 1
• Avoid FOLFIRINOX in patients >75 years or with ECOG ≥2—toxicity outweighs benefit 1, 6
• Do not perform routine surveillance imaging after curative-intent treatment—no evidence supports improved outcomes from regular follow-up 1, 6
• Avoid percutaneous biopsy of potentially resectable pancreatic masses—risk of peritoneal seeding; use EUS-guided biopsy only when diagnosis is uncertain 1